US FDA Making BsUFA III Regulatory Science Grants Available Early
Executive Summary
Up to $1m per year per award is available for projects that address significant issues with biosimilar or interchangeable product development.
You may also be interested in...
Senate’s US FDA User Fee Bill Answers Biosimilar Interchangeable Exclusivity Questions
The bill would allow for tentative interchangeable approvals, as well as shared first interchangeable exclusivity for multiple first filers.
Senate’s US FDA User Fee Bill Answers Biosimilar Interchangeable Exclusivity Questions
The bill would allow for tentative interchangeable approvals, as well as shared first interchangeable exclusivity for multiple first filers.
Remote Inspections: Stakeholders Seek Clarity As Some At US FDA Struggle With Process
Some lawmakers want FDA to prioritize in-person visits, but others are complaining that more remote inspections are needed because approvals are being delayed.